Literature DB >> 11270580

Effect of nicardipine treatment on the expression of neurofilament 200 KDa immunoreactivity in the brain of spontaneously hypertensive rats.

M Sabbatini1, F Mignini, D Venarucci, J A Vega, F Amenta.   

Abstract

Neurofilaments (NFP) are components of neuronal cytoskeleton involved primarily in axonal transport and in the regulation of dynamic activities of nerve cells. NFP consist of three subunits denominated high- (200 kDa, NFP-H), intermediate- (160 kDa, NFP-I), and low-molecular weight (68 kDa, NFP-L) neurofilament proteins. Their function and polymerization depends on phosphorylation status, and is regulated by Ca2+ influx. Ca2+ overload enhances degradation of NFP and may compromise axonal transport. An increased susceptibility to ischemia occurs in hypertension, which is also a cause of brain damage. In this study, the expression of phosphorylated NFP (P-NFP) was investigated in the brain of spontaneously hypertensive rats (SHR) using immunohistochemical techniques with antibodies against the phosphorylated epitope of NFP RT-97. Microanatomical analysis included frontal cortex, occipital cortex, hippocampus and cerebellar cortex. The effect of long-term treatment with the dihydropyridine-type Ca2+ antagonist nicardipine on the expression of P-NFP was investigated as well. In hypertension a decreased P-NFP immunoreactivity was observed in frontal and occipital cortex, in the CA1 subfield of hippocampus and in the dentate gyrus, but not in the CA3 subfield of hippocampus or in the cerebellar cortex. Treatment with a daily dose of 3 mg/kg of nicardipine and 10 mg/kg of hydralazine significantly reduced systolic pressure in SHR. The above dose of nicardipine and to a lesser extent a non-hypotensive dose of the compound (0.1 mg/kg/day), but not hydralazine, increased P-NFP immunoreactivity in the cerebral cortex and hippocampus, except the CA3 subfield. The possibility that rescued P-NFP immunoreactivity by treatment with nicardipine depends on improved brain perfusion caused by the compound and/or by countering neuronal Ca2+ overload is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11270580     DOI: 10.1081/ceh-100001204

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  3 in total

Review 1.  Prevention of dementia and cerebroprotection with antihypertensive drugs.

Authors:  Olivier Hanon; Marie Laure Seux; Hermine Lenoir; Anne Sophie Rigaud; Françoise Forette
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

2.  Cerebellar granule cells cultured from adolescent rats express functional NMDA receptors: an in vitro model for studying the developing cerebellum.

Authors:  R Lisa Popp; Jason C Reneau; Janet S Dertien
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

Review 3.  Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention.

Authors:  M Valenzuela; M Esler; K Ritchie; H Brodaty
Journal:  Transl Psychiatry       Date:  2012-04-24       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.